Medical and Health Industry Weekly (July 20 - July 24)

Joint release: Sina Pharmaceuticals, Sadie Consultants One Week Overview: Policy and regulations, the State Council issued "Deepening the reform of the medical and health system in the second half of 2020 key tasks" to comprehensively promote the reform of the medical and health system; Another 20 declared production application number status update, investment and financing, a total of 3 investment and financing incidents occurred in the domestic medical and health field, the disclosure amount of 1.119 billion yuan, foreign medical and health field a total of 7 key investment and financing events, the total amount of financing is about 165 million U.S. dollars ... Medical and health industry this week inventory, wonderful continue! A total of 7 policy and regulatory policies were issued this week, namely, "Key Tasks for Deepening the Reform of the Medical and Health System in the Second Half of 2020," "Announcement on the Conversion of Adaparin gels and dipyritoyl creams into over-the-counter drugs (No. 85 of 2020)," "On the Application of the S.Lt.E2C (R2): Regular Benefit-Risk Assessment Report (PBRER)" and the Announcement of the Guidelines for the Coordination of Technical Coordination of Human Drug Registration (No. 6 of 2020).
Table 1 The list of policy documents released this week focuses on the analysis: "Deepening the reform of the medical and health system in the second half of 2020 Key tasks" (hereinafter referred to as "Tasks") proposes six elements: strengthening the construction of public health system, deeply implementing the Healthy China Initiative, deepening the comprehensive reform of public hospitals, deepening the reform of the medical security system, improving the drug supply security system, and comprehensively promoting the relevant key reforms.
in particular, it is important that the Mission emphasizes the promotion of the revitalization and development of Chinese medicine, which is of great significance to accelerate the development of Chinese medicine innovation heritage in China.
Chinese medicine plays an important role in economic and social development as a unique health resource, huge potential economic resource, scientific and technological resources with original advantages, excellent cultural resources and important ecological resources.
the role of Chinese medicine in the prevention and treatment of common diseases, multiple morbidity, chronic diseases and difficult diseases, and major infectious diseases has been continuously demonstrated, especially in the prevention and treatment of xinguan pneumonia, Chinese medicine has played an important role in the prevention and treatment of the whole process.
the research and development of new trends in drug registration declaration, this week added 33 cases of acceptance number.
from the drug category, the largest number of chemical drug registration declarations received, 26 cases, accounting for 79%;
Figure 1 This week the national acceptance of registered declaration of drug category from the type of registration declaration, 10 cases as supplementary applications, accounting for 31%;
Figure 2 This week the national acceptance of drug registration declaration type from the declaration of enterprises, this week the largest number of enterprises accepted is Beijing Beilu Pharmaceutical Co., Ltd., the number of accepted are 3 cases, followed by Hunan Collum Pharmaceutical Co., Ltd. and Shenzhen Hua pharmaceutical Southern Pharmaceutical Co., Ltd., the number of accepted cases are 2 cases.
Figure 3 This week, the number of national enterprises to declare drug registration TOP3 consistency evaluation, this week added 11 application numbers.
from the product point of view, mainly related to iodized salsal injection, finasteride tablets, oxamine injection, sodium nitrosamine injection, linamine glucose injection, Torasemi injection, hydrochloric acid amphetamine slow release tablets, injection with meroponan 8 varieties.
from the application enterprises, Beijing Beilu Pharmaceutical Co., Ltd. the largest number of applications, the number reached 3 cases.
Form 2 This week's consistency evaluation application number list to declare the status of production, this week a total of 20 application numbers updated.
from the product point of view, mainly involved in Acapo sugar tablets, Aripitan capsules, ibuprofen injections and other 13 varieties.
from the application type, 12 varieties for generic drugs, 1 variety for biological products new drugs.
Table 3 This week reported the production status update of the application number list key analysis: This week 4 new drug declaration, 2 cases for therapeutic biological products, 1 for chemical drugs, 1 for preventive biological products.
, Parmipale capsule as the only new drug declaration, is the first new drug application submitted by Baiji Shenzhou on Parmipale.
Pamiparib (BGB-290) is a parP1 and PARP2 inhibitor in the study, and preclinical models show that they have pharmacological properties such as penetrating the blood-brain barrier and PARP-DNA complex capture, which will benefit ovarian cancer patients.
the incidence of ovarian cancer in China ranked 3rd in gynaecological malignancies, accounting for about 23% of all female reproductive tract tumors, and showed an upward trend year by year.
investment and financing trend to the domestic investment and financing market, this week in the pharmaceutical health sector a total of 3 investment and financing incidents, disclosed the amount of financing of 1.119 billion yuan.
investment targets are Seifok Gene, Deqi Pharmaceuticals, Auscom, mainly involved in precision medicine, oncology innovation drugs, biopharmaceutical fields.
, deqi pharmaceutical financing amounted to the highest amount, reaching $97 million.
Table 4 This week's domestic investment and financing event sized analysis: As the pharmaceutical industry develops, capital is paying more attention to the importance of "new global" First-in-Class technology as first-class technology is positive for driving domestic and overseas markets starting in 2018.
and Dege Pharma, which specializes in developing first-in-Class's innovative anti-tumor therapy, is once again recognized in the capital markets after receiving $120 million in financing in 2018.
overseas investment and financing market, there were seven key investment and financing events in the medical and health sector this week, with a total disclosure of about $165 million, with companies such as Neurovalens, Locate Bio and Belkin Laser, mainly involved in medical devices, medical services, medicine and other fields.
, Encoded Therapeutics received the highest amount of $135 million in financing.
Table 5 This week's Highlights of Overseas Investment and Financing Events: Funds from Encoded Therapeutics, which is dedicated to the development of precision gene therapy, will be used to promote its precision gene therapy for the treatment of Dravet syndrome.
Dravet syndrome is a type of refractive epilepsy syndrome, which occurs in fancy, with fever-related convulsive seizures at first, followed by a variety of types of non-feveral convulsions including myoclonus, accompanied by regressive psychosis.
2018, the subtype Dravet syndrome (severe myoclonic epilepsy in infants) of epilepsy was included in the "First Rare Disease Sr."
.